AU Patent

AU2025217395A1 — Assays for diagnosing and evaluating treatment options for fabry disease

Assigned to Amicus Therapeutics Inc · Expires 2025-09-04 · 1y expired

What this patent protects

#$%^&*AU2025217395A120250904.pdf##### Abstract Provided are in vitro and in vivo methods for determining whether a patient with Fabry disease will respond to treatment with a specific pharmacological chaperone. Further provided are compositions comprising 1- deoxygalactonoji…

USPTO Abstract

#$%^&*AU2025217395A120250904.pdf##### Abstract Provided are in vitro and in vivo methods for determining whether a patient with Fabry disease will respond to treatment with a specific pharmacological chaperone. Further provided are compositions comprising 1- deoxygalactonojirimycin or a salt thereof. Abstract Provided are in vitro and in vivo methods for determining whether a patient with Fabry disease will respond to treatment with a specific pharmacological chaperone. Further provided are compositions comprising 1- deoxygalactonojirimycin or a salt thereof.

Drugs covered by this patent

Patent Metadata

Patent number
AU2025217395A1
Jurisdiction
AU
Classification
—
Expires
2025-09-04
Drug substance claim
No
Drug product claim
No
Assignee
Amicus Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.